Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or non-pregnant female aged 18 to 65 years hospitalized with moderate COVID-19 infection: body temperature \> 37.5 °C; respiratory rate \> 22/min; shortness of breath during physical exertion; typical coronavirus-associated chest computed tomography (CT) changes (CT1- CT2); pulse oximetry levels SpO2\< 95%.~2. Able to give informed consent and attend all study visits~3. Positive PCR-test for COVID-19 ≤72 hours prior to randomization~4. The patient's ability to inhale the experimental drug~5. Participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month~Key Exclusion Criteria:~1. Fever \> 38.5°C.~2. Cough severity is less than 1 point on a 4-point scale.~3. Respiratory rate \> is more than 30 / min~4. SpO2 ≤ 93%.~5. Decreased level of consciousness, agitation.~6. Unstable hemodynamics (systolic blood pressure less than 100 mmHg or diastolic blood pressure less than 60 mmHg).~7. The need to require mechanical ventilation beyond the screening/ randomization.~8. Long-term systemic corticosteroid exposure.~9. Autoimmune or inflammatory diseases (systemic / localized).~10. Positive blood tests for HIV, hepatitis B and С, syphilis.~11. Pregnancy and breast-feeding~12. Previous adverse reactions to the active substance and/or excipients included in the drug.~13. Any use of anti-viral medications or immunomodulatory agents up to 7 days before participating in the study~14. Chronic diseases of the cardiovascular system~15. Type 1 diabetes~16. The following laboratory parameters are excluded:~    Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total and direct bilirubin \>4 x upper limit of normal (ULN);~17. Treatment with any medicine that have a pronounced effects on the blood coagulation system (expect for COVID-19 treatment), including combined oral contraceptives.~18. Treatment with any medicine that can affect cardiac conduction~19. Participation in other investigational drug or device clinical trials within 90 days prior to screening.~20. History of alcohol, drug or chemical abuse.~21. Mental illness.~22. Receipt of plasma from a person who recovered from COVID-19 (convalescent plasma) up to 14 days before participating in the study, vaccination against SARS-CoV-2 , the need for extracorporeal membrane oxygenation.~23. Any conditions that, according to the researcher's, may be a contraindication to the participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MIR 19 ® (Type: EXPERIMENTAL): Study participants from experimental groups, in addition to standard COVID-19 therapy, received the MIR 19 ® (2 inhalations per day with a single dose of 1.85 or 5.55 mg at intervals of 7-8 hours for 14 days).The standard therapy in this group included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
- Standard COVID-19 therapy (Type: ACTIVE_COMPARATOR): In the comparison group, therapy was carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection.The standard therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.

Based on this trial design, predict the completion outcome and termination type (if applicable).